Zobrazeno 1 - 10 of 84 pro vyhledávání: '"Steven M. Fruchtman"'
1
Abstract A020: CETSA profiling unveils novel targets engaged by anti-tumor drug rigosertib to inhibit RAS-MAPK signaling and trigger NLRP3 inflammasome activation
Autor: Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Alexey Chernobrovkin, Kristina Riegel, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v: Molecular Cancer Research. 21:A020-A020
Background: The importance of styryl benzyl sulfones that induce G2/M cell cycle arrest and apoptosis in tumor cells has raised interest in cancer therapeutics. Rigosertib (ON 01910.Na) has been characterized as a disruptor of multiple signaling path
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46ac2620f1eb4e2011ba42ba6275d4ba
https://doi.org/10.1158/1557-3125.ras23-a020
Zobrazit plný text záznamu
2
Abstract 5987: Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth
Autor: Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Juliane Mooz, Mahil Lambert, Volker Dötsch, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v: Cancer Research. 83:5987-5987
CDK4/6 inhibitors are clinically approved for the treatment of HR+, HER2- metastatic breast cancer by reinstating the G1/S checkpoint in tumor cells. Despite clinical benefit, safety concerns such as neutropenia and diarrhea, and disease progression,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3a7d13e016417d7bff0da62445e30a8
https://doi.org/10.1158/1538-7445.am2023-5987
Zobrazit plný text záznamu
3
Narazaciclib’s kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models
Autor: Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam
Publikováno v: Journal of Clinical Oncology. 40:e15096-e15096
e15096 Background: Despite clinical benefit of CDK4/6 inhibitors in HR+Her2-mBC, patients progress. Neutropenia and diarrhea are safety concerns. Narazaciclib (ON 123300) is a multi-targeted kinase inhibitor of CDK4/6, ARK5 (NUAK1), CSF1R, and c-Kit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3722c13f3a4efffdf552c28ee1507c19
https://doi.org/10.1200/jco.2022.40.16_suppl.e15096
Zobrazit plný text záznamu
4
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
Autor: Shyamala C. Navada, Patrick S. Zbyszewski, Richard C. Woodman, Naveen Pemmaraju, Rosmy B. John, Guillermo Garcia-Manero, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, Steven M. Fruchtman, Maro Ohanian, Yesid Alvarado, Manoj Maniar
Publikováno v: Leukemia research. 94
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML; n = 1) who were either hypomethylating agent naive (n = 10) or re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd5bd23ecb36503901cee3ce395699a
https://pubmed.ncbi.nlm.nih.gov/32442785
Zobrazit plný text záznamu
6
Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial
Autor: Ken Furudate, Aref Al-Kali, David Valcárcel, Matthew Parris, Selina M. Luger, Anna Jonasova, Patrick S. Zbyszewski, María Díez-Campelo, Guillermo Garcia-Manero, Erica D. Warlick, Koichi Takahashi, Steven M. Fruchtman, Michael K Keng, Feng Wang
Publikováno v: Blood. 138:1517-1517
Background: Hypomethylating agents (HMA) are well established standard of care for patients (pts) with higher-risk MDS (HR-MDS). However, approximately half of the pts do not respond to HMA therapy and most of the responders eventually lose response
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cff3e26f655a64d1629faee2219fd5b
https://doi.org/10.1182/blood-2021-152048
Zobrazit plný text záznamu
7
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
Autor: Eunice Chang, Steven M. Fruchtman, Tanya G K Bentley, Michael E. Petrone, Sandra E. Kurtin, Michael S. Broder, Sudipto Mukherjee, Christopher R. Cogle, Scott Megaffin
Publikováno v: The Oncologist. 22:379-385
Background Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b74a9182e64dc204a8eb16a13f32f2
https://doi.org/10.1634/theoncologist.2016-0211
Zobrazit plný text záznamu
9
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
Autor: Rosalie Odchimar-Reissig, Erin P. Demakos, Shyamala C. Navada, Michael E. Petrone, Patrick S. Zbyszewski, Lewis R. Silverman, James F. Holland, Steven M. Fruchtman
Publikováno v: Leukemia research. 64
This Phase 1/2, dose-escalating study of rigosertib enrolled 22 patients with higher-risk myelodysplastic syndromes (MDS) (n=9) and acute myeloid leukemia (AML; n=13) who had relapsed or were refractory to standard therapy and for whom no second-line
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a5dfda58ccaedaedd71e1c3e55a994
https://pubmed.ncbi.nlm.nih.gov/29144985
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje